Multimodal Interventions for Autism

(GARM-Autism Trial)

This trial explores new treatments for autism spectrum disorder (ASD), aiming to improve social communication, behavior, and address gut and metabolic issues. Researchers are testing a combination of therapies, including stem cells (Autologous cSVF + MSCs), gut bacteria transplant (FMT, Fecal Material Transplantation), and dietary changes (Ketogenic RESET Diet Protocol), to determine their combined effectiveness. Individuals stable on their current autism medications or therapies, with or without gut-related symptoms, might be suitable candidates for this trial. As a Phase 1 and Phase 2 trial, the research seeks to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking advancements in ASD treatment.

The trial requires that you are stable on your current medications or therapy, so you do not need to stop taking them. However, you should not have taken antibiotics or probiotics in the last 30 days.

Previous studies have shown promising safety results for the treatments explored in this trial. Research indicates that mesenchymal stem cells (MSCs) are generally well-tolerated in children with autism spectrum disorder (ASD). One study found that these cells did not cause major side effects in patients, suggesting that using a person's own cSVF and stored MSCs could be safe for participants.

For fecal microbiota transplantation (FMT), studies have shown it might help reduce digestive issues and improve some ASD symptoms. However, safety concerns exist, and more research is needed to confirm these findings.

Regarding the ketogenic diet, studies suggest it could be a safe option for people with ASD. It has been linked to improvements in behavior and thinking skills, without significant safety concerns reported.

Researchers are excited about the use of autologous cSVF (stromal vascular fraction) and MSCs (mesenchymal stem cells) for autism because, unlike traditional behavioral and pharmaceutical therapies, they offer a regenerative and personalized approach. These cells are derived from the patient's own body, reducing the risk of rejection and potentially promoting healing at a cellular level. This multimodal approach not only targets symptoms but also addresses underlying biological factors like diet, gut flora, and autoimmune responses, which are not typically covered by current treatments. By focusing on these innovative mechanisms, this treatment has the potential to provide more comprehensive improvements in behavior, learning, and communication for individuals with autism.

Research has shown that treatments using mesenchymal stem cells (MSCs) may help with autism. One study found that children with autism improved in key symptoms after a single MSC treatment. In this trial, participants may receive an autologous cSVF + MSCs (cryo) treatment as part of a multimodal approach. Another approach under study is fecal microbiota transplantation (FMT), which has been linked to significant improvements; some studies have noted up to a 50% reduction in symptoms over time. Additionally, the ketogenic RESET diet protocol, high in fat and low in carbohydrates, is being evaluated for its potential to improve behavior by boosting energy use and reducing stress in the body. Together, these combined approaches, which focus on reducing inflammation, improving gut health, and enhancing metabolism, offer hope for people with autism.¹³⁶⁷⁸